Sacituzumab Govitecan, a Novel Treatment for Patients with mTNBC

Sacituzumab Govitecan, a Novel Treatment for Patients with mTNBC

0 0 about 1 month ago
In this episode of The Onco'Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland and Sperber talk about sacituzumab govitecan, a novel antibody-drug conjugate. At the time of the interview, the drug was not yet approved, but in the weeks following the interview, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan (Trodelvy™) for the treatment of adult patients with metastatic triple-negative breast cancer ... See More

Find us on Facebook

iAB member
Copyright 2020 - Spreaker Inc. a Voxnest Company - Create a podcast - New York, NY
Help